RESUMO
INTRODUCTION: Pain and spasms of urinary and biliary tracts are conditions causing poor quality of life. Treatment with analgesic drugs such as non-steroidal anti-inflammatory drugs and modulators of the parasympathetic system are not always tolerated, and often additional therapeutic options are necessary. The present analysis aimed to evaluate the pharmacokinetics and effectiveness of oral and parenteral preparations based on phloroglucinol in reducing pain and spasms associated with renal or biliary colic in phase 3, multicentre, open-label, randomized, comparative studies on clinical effectiveness and safety. METHODS: Pharmacokinetic and pharmacodynamic studies were carried out. Four phase 3 multicentre, open-label, randomized, comparative studies were conducted to evaluate the clinical effectiveness and safety in patients with pain and spasms of urinary or biliary tracts. Eligible patients randomly received either phloroglucinol orally or via intramuscular (IM)/intravenous (IV) administration and reference drug, dexketoprofen for urinary spasms and pain, the non-steroidal anti-inflammatory drug metamizole or scopolamine-based reference drug for biliary colic. The primary outcomes were symptoms and observed frequency of spasms, while the secondary outcome was the duration of improvement or the time between the drug administration and the recurrence of symptoms. Comparison of groups by quantitative characteristics was performed using the T-test for independent samples or the Mann-Whitney test. Intragroup comparisons were performed using the Wilcoxon test, or the T-test for linked samples. Qualitative signs were analysed using the Pearson's χ2 test and Fisher's exact test. RESULTS: The pharmacokinetic studies showed that (i) most of the phloroglucinol (> 80% for IV and per os formulations) was eliminated in the first 6 h after dosing, (ii) the drug was eliminated in urine as unchanged phloroglucinol (1,3,5-trihydroxybenzene) in a small proportion (< 3% of the dose) and (iii) a considerable amount of the drug was detected after enzymatic deconjugation with ß-glucoronidase/arylsulfatase from Helix pomatia. As for the pharmacokinetic study, a total of 364 patients were enrolled, divided in four studies: two designed to test the effectiveness of oral and IM/IV preparations in biliary colic and two in urinary colic. Baseline characteristics between groups were similar. Phloroglucinol oral or IV/IM showed an effectiveness comparable to the reference drug in reducing pain and spasms associated with both urinary and biliary colic. There was no difference between all groups by survival analysis. CONCLUSION: Oral and parenteral preparations based on phloroglucinol are as effective in reducing pain and spasms associated with renal or biliary colic as current therapeutic options. Therefore, phloroglucinol may be considered as useful to treat pain and spasms associated with urinary and biliary colic.
Assuntos
Cólica , Humanos , Cólica/tratamento farmacológico , Floroglucinol/efeitos adversos , Qualidade de Vida , Anti-Inflamatórios não Esteroides/uso terapêutico , Dor/tratamento farmacológico , Dor/etiologia , Espasmo/tratamento farmacológico , Resultado do TratamentoRESUMO
Objective: The purpose of this study was to investigate the efficacy and safety of phloroglucinol in combination with oxytocin in the induction of labor in women who had experienced term premature rupture of membranes (PROM). Methods: Data from 100 women who experienced PROM between December 2020 and December 2021 were retrospectively evaluated in this study. The puerperae were categorized into observation and control groups based on their uterine contraction regimens. The observation group consisted of 53 participants that had been treated with phloroglucinol in combination with oxytocin, and the control group consisted of 47 participants that had been treated with oxytocin alone. It was observed and compared in terms of the Bishop score before and after the administration of the puerpera to see which group had the best index. A study was performed after the drug was administered to examine its effects on the duration of labor (including the first, second, and third stages of labor), the mode of delivery (including natural vaginal delivery and cesarean section), the incidence of adverse pregnancy outcomes (fetal distress and neonatal asphyxia), successful labor induction, and complication rates. Results: Patients in the observation group had a significantly higher Bishop score after administration than those in the control group (P < 0.05), although there was no difference between the two groups before administration. In comparison to the control group, the observation group had a significantly higher efficacy rate for drug administration (P < 0.05), as well as a significantly lower occurrence of the first stage of labor (P < 0.05), a higher rate of vaginal natural delivery and successful induction of labor (P < 0.05), and a significantly lower incidence of adverse pregnancy outcomes and complications (P < 0.05). Conclusion: In conclusion, the use of phloroglucinol in combination with intravenous oxytocin in the process of promoting cervical ripening and induction of labor for women with PROM who are at term was investigated. This study could help women speed up cervical dilation, improve the cervical Bishop scores, shorten the total labour process, improve the effective rate of vaginal delivery, and be very safe, making it a good candidate for clinical promotion and application.
Assuntos
Ocitócicos , Ocitocina , Maturidade Cervical , Cesárea , Feminino , Humanos , Recém-Nascido , Trabalho de Parto Induzido , Ocitócicos/efeitos adversos , Ocitocina/efeitos adversos , Medidas de Resultados Relatados pelo Paciente , Floroglucinol/efeitos adversos , Gravidez , Estudos RetrospectivosRESUMO
BACKGROUND: Anti-spasmodic agents are commonly injected during esophagogastroduodenoscopy (EGD) to improve visualization of the gastric mucosa by inhibiting gastrointestinal (GI) peristalsis. The availability of oral anti-spasmodic agents would increase convenience. In this study, we evaluated the effectiveness of oral phloroglucinol (Flospan®) as a premedication for unsedated EGD. METHODS: A prospective, double-blinded, placebo-controlled, randomized controlled trial was conducted in a tertiary hospital. Individuals scheduled to undergo unsedated EGD were randomly assigned to receive either oral phloroglucinol or matching placebo 15 min before EGD. The primary outcome was the rate of complete gastric peristalsis suppression. Outcomes were assessed by independent investigators according to the classification of gastric peristalsis and ease of intragastric observation at the beginning (Period A) and end (Period B) of EGD. RESULTS: Overall, 71 phloroglucinol-treated and 71 placebo-treated participants (n = 142 total) were included. The phloroglucinol group showed significantly higher proportions of participants with complete gastric peristalsis suppression than the placebo group (22.5% vs. 9.9%, P = 0.040). The ease of intragastric observation was significantly better in the phloroglucinol group than in the placebo group at Periods A (P < 0.001) and B (P = 0.005). Patients in both groups had comparable adverse events and showed willingness to take the premedication at their next examination. CONCLUSIONS: Oral phloroglucinol significantly suppressed gastrointestinal peristalsis during unsedated EGD compared with placebo (Clinical trial registration number: NCT03342118).
Assuntos
Endoscopia do Sistema Digestório , Floroglucinol/administração & dosagem , Pré-Medicação , Administração Oral , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Peristaltismo/efeitos dos fármacos , Floroglucinol/efeitos adversos , Floroglucinol/farmacologia , Placebos , Estudos Prospectivos , Resultado do TratamentoRESUMO
BACKGROUND: To compare the clinical efficacy and safety of phloroglucinol (PHL) and magnesium sulfate (MS) in the treatment of threatened abortion through systematic review. METHODS: Foreign databases, such as the Cochrane Library, PubMed and EMBASE, and Chinese databases, including the China Biology Medicine disc (SinoMed), China National Knowledge Infrastructure (CNKI), Chongqing VIP (VIP) and WanFang Data, were searched. Published randomized controlled trials (RCTs) documents obtained from these databases were included if they were associated with the research objective. The search timeframe was from the beginning of the establishment of each database to May 2018. Document selection, data abstraction and document quality evaluation were independently performed by 2 investigators. A combined analysis of the data was performed for those documents that fulfilled the study requirements; Rev Man 5.3 and Stata 12.0 software were used to compare and analyze the 2 drugs in terms of the total effective rate (TER), rate of adverse events, time required to relieve uterine contractions, onset time, time of complete relief of uterine contraction symptoms, medication duration and length of hospital stay. RESULTS: A total of 21 RCT trials were included in the present research, according to the inclusion criteria. However, the quality of the included studies was low. The meta-analysis suggested that the TER and drug onset time of PHL were higher than those for MS, while the rate of adverse events, the time required to relieve uterine contractions, time to complete relief of uterine contraction symptoms, drug continuous treatment time and length of hospital stay were shorter than those for MS. CONCLUSION: The clinical efficacy of PHL is better than that of MS, and PHL obviously results in fewer adverse reactions than MS. However, due to poor quality of evidence, high quality, multi-center RCTs with large samples are required for further verification.
Assuntos
Ameaça de Aborto/tratamento farmacológico , Sulfato de Magnésio/uso terapêutico , Floroglucinol/uso terapêutico , Substâncias para o Controle da Reprodução/uso terapêutico , Feminino , Humanos , Sulfato de Magnésio/efeitos adversos , Floroglucinol/efeitos adversos , Gravidez , Ensaios Clínicos Controlados Aleatórios como Assunto , Substâncias para o Controle da Reprodução/efeitos adversosRESUMO
OBJECTIVE: The aim of this study was to review herb-drug interaction studies with St John's wort (Hypericum perforatum L.) with a focus on the hyperforin content of the extracts used in these studies. METHODS: PUBMED was systematically searched to identify studies describing pharmacokinetic interactions involving St John's wort. Data on study design and the St John's wort extract or product were gathered to extract hyperforin content and daily dose used in interaction studies. KEY FINDINGS: This analysis demonstrates that significant herb-drug interactions (resulting in a substantial change in systemic exposure) with St John's wort products were associated with hyperforin daily dosage. Products that had a daily dose of <1 mg hyperforin were less likely to be associated with major interaction for drugs that were CYP3A4 or p-glycoprotein substrates. Although a risk of interactions cannot be excluded even for low-dose hyperforin St. John's wort extracts, the use of products that result in a dose of not more than 1 mg hyperforin per day is recommended to minimise the risk of interactions. CONCLUSIONS: This review highlights that the significance of herb-drug interactions with St John's wort is influenced by the nature of the herbal medicines product, particularly the hyperforin content.
Assuntos
Interações Ervas-Drogas , Hypericum/química , Floroglucinol/análogos & derivados , Terpenos/administração & dosagem , Animais , Relação Dose-Resposta a Droga , Humanos , Farmacocinética , Floroglucinol/administração & dosagem , Floroglucinol/efeitos adversos , Floroglucinol/isolamento & purificação , Extratos Vegetais/administração & dosagem , Extratos Vegetais/efeitos adversos , Extratos Vegetais/química , Terpenos/efeitos adversos , Terpenos/isolamento & purificaçãoRESUMO
BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a severe drug eruption. We report herein the first case of AGEP induced by phloroglucinol (Spasfon®). PATIENTS AND METHODS: A 27-year-old pregnant woman developed a febrile exanthematous pustulosis eruption three days after treatment with intravenous phloroglucinol and paracetamol for nephritic colic. She had no previous history of psoriasis. The laboratory workup showed hyperleukocytosis with neutrophilia. A cytobacteriological sample of the pustules was negative. Skin biopsy revealed marked neutrophilic and leukocytoclastic vasculitis. Reintroduction of phloroglucinol after delivery resulted in the same clinical symptoms within a few hours of intake. A diagnosis of phloroglucinol-induced AGEP was made on the basis of intrinsic imputability of I4 (S3 C3) using the imputability criteria of Begaud et al. The outcome was favorable after withdrawal of the drug. DISCUSSION: To the best of our knowledge, this is the first case of phloroglucinol-induced AGEP confirmed by reintroduction of the drug.
Assuntos
Pustulose Exantematosa Aguda Generalizada/diagnóstico , Pustulose Exantematosa Aguda Generalizada/etiologia , Indicadores e Reagentes/efeitos adversos , Floroglucinol/efeitos adversos , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/etiologia , Acetaminofen/administração & dosagem , Antipiréticos/administração & dosagem , Biópsia , Feminino , Humanos , Gravidez , Cólica Renal/tratamento farmacológico , Pele/patologiaRESUMO
To observe the effect of phloroglucinol on plasma angiotensin II and D-dimer index when it was applied to patients with severe pregnancy-induced hypertension. 212 cases of severe pregnancy-induced hypertension patients diagnosed clinically were selected to be randomly divided into the research group and the control group. The research groups were given phloroglucinol, while the control groups were given magnesium sulfate. The plasma angiotensin II and D-dimer index in patients were detected before treatment and after 7 days respectively with statistical analysis of results. The diffidence after treatment was statistically significant (P<0.05). Compared within the same group, the difference of each index before and after treatment in the research group was statistically significant (P<0.05), while the control group was not statistically significant (P>0.05). It showed that the research group could reduce the plasma D-dimer and angiotensin II index in severe pregnancy-induced hypertension patients, and its effect was significantly better than the control group according to the plasma D-dimer and angiotensin II index changes in patients, it indicated that it was effective of phloroglucinol treatment for patients with pregnancy-induced hypertension disease and superior to the western medicine conventional treatment, worth clinical promotion.
Assuntos
Angiotensina II/sangue , Anti-Hipertensivos/uso terapêutico , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Hipertensão Induzida pela Gravidez/tratamento farmacológico , Floroglucinol/uso terapêutico , Adulto , Anti-Hipertensivos/efeitos adversos , Anti-Hipertensivos/farmacologia , Feminino , Humanos , Hipertensão Induzida pela Gravidez/sangue , Floroglucinol/efeitos adversos , Floroglucinol/farmacologia , GravidezAssuntos
Toxidermias/etiologia , Fármacos Gastrointestinais/efeitos adversos , Hipersensibilidade Imediata/induzido quimicamente , Floroglucinol/efeitos adversos , Adolescente , Domperidona/uso terapêutico , Combinação de Medicamentos , Fármacos Gastrointestinais/metabolismo , Fármacos Gastrointestinais/uso terapêutico , Humanos , Masculino , Floroglucinol/metabolismoAssuntos
Anafilaxia/imunologia , Hipersensibilidade a Drogas/imunologia , Floroglucinol/efeitos adversos , Anafilaxia/diagnóstico , Combinação de Medicamentos , Hipersensibilidade a Drogas/diagnóstico , Feminino , Humanos , Imunoglobulina E/sangue , Imunoglobulina E/imunologia , Testes Cutâneos , Adulto JovemRESUMO
The aim of this study was to compare the effectiveness and safety of intramuscular phloroglucinol and oral misoprostol for cervix pretreatment before diagnostic hysteroscopy. Several modalities for cervical priming and pain reduction have been adopted to reduce the complications related to cervical dilatation before hysteroscopy. Among them, the prostaglandin analog misoprostol is the most frequently used agent. Phloroglucinol, a spasmolytic, has also been showed to have an effect in inducing cervical dilatation but is rarely used before hysteroscopy. One hundred twenty outpatients undergoing anesthesia-free diagnostic hysteroscopy were randomly assigned to receive 80 mg intramuscular phloroglucinol and 400 mg oral misoprostol before diagnostic hysteroscopy. The main outcome measures were preoperative cervical width, visual analog scales (VAS) for pain, cervical passage time, and adverse reactions. Intramuscular phloroglucinol resulted in a significantly wider cervical width, lower VAS pain score, shorter cervical passage time, and a lower adverse effects rate compared with oral misoprostol. Intramuscular phloroglucinol is more effective and safer than oral misoprostol in inducing proper cervical priming and may be the optimal choice for cervical pretreatment before diagnostic hysteroscopy.
Assuntos
Histeroscopia/métodos , Misoprostol/administração & dosagem , Ocitócicos/administração & dosagem , Parassimpatolíticos/administração & dosagem , Floroglucinol/administração & dosagem , Administração Oral , Adulto , Feminino , Humanos , Injeções Intramusculares , Misoprostol/efeitos adversos , Ocitócicos/efeitos adversos , Parassimpatolíticos/efeitos adversos , Floroglucinol/efeitos adversos , Estudos ProspectivosRESUMO
Although individual phlorotannins contained in the edible brown algae have been reported to possess strong anti-inflammatory activity, the responsible components of Eisenia bicyclis have yet to be fully studied. Thus, we evaluated their anti-inflammatory activity via inhibition against production of lipopolysaccharide (LPS)-induced nitric oxide (NO) and tert-butylhydroperoxide (t-BHP)-induced reactive oxygen species (ROS), along with suppression against expression of inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), in RAW 264.7 cells. The anti-inflammatory activity potential of the methanolic extract and its fractions of E. bicyclis was in the order of dichloromethane>methanol>ethyl acetate>n-butanol. The strong anti-inflammatory dichloromethane fraction was further purified to yield fucosterol. From the ethyl acetate fraction, six known phlorotannins were isolated: phloroglucinol, eckol, dieckol, 7-phloroeckol, phlorofucofuroeckol A and dioxinodehydroeckol. We found that these compounds, at non-toxic concentrations, dose-dependently inhibited LPS-induced NO production. Fucosterol also inhibited t-BHP-induced ROS generation and suppressed the expression of iNOS and COX-2. These results indicate that E. bicyclis and its constituents exhibited anti-inflammatory activity which might attribute to inhibition of NO and ROS generation and suppression of the NF-κB pathway and can therefore be considered as a useful therapeutic and preventive approach to various inflammatory and oxidative stress-related diseases.
Assuntos
Anti-Inflamatórios/metabolismo , Dioxanos/farmacologia , Alimento Funcional/análise , Kelp/química , Macrófagos/efeitos dos fármacos , Floroglucinol/análogos & derivados , Extratos Vegetais/farmacologia , Estigmasterol/análogos & derivados , Animais , Anti-Inflamatórios/análise , Anti-Inflamatórios/química , Anti-Inflamatórios/isolamento & purificação , Linhagem Celular Transformada , Sobrevivência Celular/efeitos dos fármacos , Ciclo-Oxigenase 2/química , Ciclo-Oxigenase 2/metabolismo , Dioxanos/efeitos adversos , Dioxanos/análise , Dioxanos/isolamento & purificação , Regulação para Baixo/efeitos dos fármacos , Macrófagos/enzimologia , Macrófagos/imunologia , Macrófagos/metabolismo , Camundongos , Óxido Nítrico/antagonistas & inibidores , Óxido Nítrico/metabolismo , Óxido Nítrico Sintase Tipo II/antagonistas & inibidores , Óxido Nítrico Sintase Tipo II/metabolismo , Concentração Osmolar , Estresse Oxidativo/efeitos dos fármacos , Floroglucinol/efeitos adversos , Floroglucinol/análise , Floroglucinol/isolamento & purificação , Floroglucinol/farmacologia , Extratos Vegetais/efeitos adversos , Extratos Vegetais/química , Extratos Vegetais/isolamento & purificação , Folhas de Planta/química , Espécies Reativas de Oxigênio/antagonistas & inibidores , Espécies Reativas de Oxigênio/metabolismo , República da Coreia , Solventes/química , Estigmasterol/efeitos adversos , Estigmasterol/análise , Estigmasterol/isolamento & purificação , Estigmasterol/farmacologiaRESUMO
Therapeutic agents exert their pharmacological and adverse effects by interacting with molecular targets. Even if drug molecules are intended to interact with specific targets in a desirable manner, they are often found to bind to other targets. Nowadays, research is focused on a single molecule that simultaneously targets multiple disease-causing proteins. Therefore, off-target identification of existing chemical space can be a valuable tool to find safe and effective multi-targeted therapeutic agents at a significantly lower cost to patients. Phloroglucinols represent a class of compounds, which exhibits a diverse range of biological activities, such as anti-HIV, antimalarial, antileishmanial, antituberculosis, antibacterial, and antifungal. The aim of the current study is to explore untapped potential of various series of phloroglucinols against HIV reverse transcriptase (HIV-RTase). A series of filtering parameters was applied in search of viable phloroglucinol derivatives against HIV-RTase. A library of phloroglucinol derivatives was screened based on their toxicity potential followed by predicted ADME parameters. The filtered compounds were then carried forward for docking analysis against HIV-RTase. A set of 37 phloroglucinol compounds with diverse pharmacological profile was found to have good binding affinity towards HIV-RTase. These molecules formed hydrogen bonds with Lys101, Lys103, Val106, and Leu234 residues and ππ stacking interaction with Tyr318 residue of the protein. Here, we propose potential phloroglucinol derivatives with different known biological activity that can be repurposed as potential hits against HIV.
Assuntos
Fármacos Anti-HIV/farmacologia , Transcriptase Reversa do HIV/antagonistas & inibidores , Floroglucinol , Inibidores da Transcriptase Reversa/farmacologia , Fármacos Anti-HIV/química , Sítios de Ligação , Desenho de Fármacos , Transcriptase Reversa do HIV/química , Transcriptase Reversa do HIV/metabolismo , Ensaios de Triagem em Larga Escala , Interações Hidrofóbicas e Hidrofílicas , Simulação de Acoplamento Molecular , Floroglucinol/efeitos adversos , Floroglucinol/análogos & derivados , Floroglucinol/farmacologia , Ligação Proteica , Inibidores da Transcriptase Reversa/químicaRESUMO
Hyperforin is a prenylated phloroglucinol present in the medicinal plant St John's wort (Hypericum perforatum). The compound has many biological properties, including antidepressant, anti-inflammatory, antibacterial and antitumor activities. This review focuses on the in vitro antileukemic effects of purified hyperforin and related mechanisms in chronic lymphoid leukemia (CLL) and acute myeloid leukemia (AML) - conditions that are known for their resistance to chemotherapy. Hyperforin induces apoptosis in both CLL and AML cells. In AML cell lines and primary AML cells, hyperforin directly inhibits the kinase activity of the serine/threonine protein kinase B/AKT1, leading to activation of the pro-apoptotic Bcl-2 family protein Bad through its non-phosphorylation by AKT1. In primary CLL cells, hyperforin acts by stimulating the expression of the pro-apoptotic Bcl-2 family member Noxa (possibly through the inhibition of proteasome activity). Other hyperforin targets include matrix metalloproteinase-2 in AML cells and vascular endothelial growth factor and matrix metalloproteinase-9 in CLL cells - two mediators of cell migration and angiogenesis. In summary, hyperforin targets molecules involved in signaling pathways that control leukemic cell proliferation, survival, apoptosis, migration and angiogenesis. Hyperforin also downregulates the expression of P-glycoprotein, a protein that is involved in the resistance of leukemia cells to chemotherapeutic agents. Lastly, native hyperforin and its stable derivatives show interesting in vivo properties in animal models. In view of their low toxicity, hyperforin and its derivatives are promising antileukemic agents and deserve further investigation in vivo.
Assuntos
Antineoplásicos Fitogênicos/farmacologia , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Leucemia Mieloide Aguda/tratamento farmacológico , Floroglucinol/análogos & derivados , Terpenos/farmacologia , Subfamília B de Transportador de Cassetes de Ligação de ATP , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Animais , Antineoplásicos Fitogênicos/efeitos adversos , Antineoplásicos Fitogênicos/uso terapêutico , Apoptose/efeitos dos fármacos , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Leucemia Linfocítica Crônica de Células B/enzimologia , Leucemia Linfocítica Crônica de Células B/metabolismo , Leucemia Mieloide Aguda/enzimologia , Leucemia Mieloide Aguda/metabolismo , Leucócitos/efeitos dos fármacos , Leucócitos/enzimologia , Leucócitos/metabolismo , Proteínas de Neoplasias/antagonistas & inibidores , Floroglucinol/efeitos adversos , Floroglucinol/farmacologia , Floroglucinol/uso terapêutico , Complexo de Endopeptidases do Proteassoma/efeitos dos fármacos , Complexo de Endopeptidases do Proteassoma/metabolismo , Inibidores de Proteínas Quinases/efeitos adversos , Inibidores de Proteínas Quinases/farmacologia , Inibidores de Proteínas Quinases/uso terapêutico , Proteínas Proto-Oncogênicas c-akt/antagonistas & inibidores , Proteínas Proto-Oncogênicas c-akt/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2/biossíntese , Proteínas Proto-Oncogênicas c-bcl-2/genética , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Transdução de Sinais/efeitos dos fármacos , Terpenos/efeitos adversos , Terpenos/uso terapêuticoRESUMO
OBJECTIVE: Phloroglucinol is used to prevent gastric, intestine or urogenital spasms. In France, many pregnant women are exposed to phloroglucinol for which no data are available about its use in pregnancy. The present study, using EFEMERIS database, investigates potential teratogenic risk of phloroglucinol in pregnancy. MATERIALS AND METHODS: EFEMERIS is a database including prescribed and delivered drugs during pregnancy (data from Caisse Primaire d'Assurance Maladie of Haute-Garonne) and outcomes (data from Maternal and Infant Protection Service and from Antenatal diagnostic Centre). Women delivered from July 1st 2004 to June 30th 2008 in Haute-Garonne and registered in the French Health Insurance Service were included into EFEMERIS database. We compared pregnancy outcomes and newborn health between women exposed to phloroglucinol during organogenesis and non-exposed women. Malformations were classified according to Eurocat classification. RESULTS: Five thousand one hundred and thirty-two newborns (12.7%) exposed during organogenesis to phloroglucinol were compared to 35,223 controls (non exposed newborns). The mean number of different drugs prescribed during the first trimester of pregnancy per woman was higher in women exposed to phloroglucinol than in non-exposed women (6.4 ± 4.3 versus 2.4 ± 3.3, P < 10(-4)). Among newborns, 126 (2.5%) had a malformation versus 804 (2.3%) in control newborns (OR=1.1, [0.9-1.3]). The present study was powered to find a 1.3 fold increase in the overall rate of major anomalies. DISCUSSION AND CONCLUSION: This first epidemiologic study about phloroglucinol in pregnancy does not support evidence of a teratogenic risk for phloroglucinol in humans.
Assuntos
Anormalidades Induzidas por Medicamentos/epidemiologia , Anormalidades Induzidas por Medicamentos/etiologia , Floroglucinol/efeitos adversos , Adulto , Estudos de Coortes , Feminino , Humanos , Recém-Nascido , Gravidez , Primeiro Trimestre da Gravidez , Medição de RiscoRESUMO
Vascular endothelial growth factor (VEGF) is a key player in neo-angiogenesis; it sustains the progression of solid neoplasias, brain tumours included. It has recently been demonstrated that the use of antidepressants correlates with increasing VEGF levels in the central nervous system (CNS). In order to elucidate whether the most used natural antidepressant [St. John's wort (SJW) extract] modulates VEGF expression, possible relationship between≤µM hyperforin (Hyp, the bioactive component in SJW) and VEGF in CNS tumours has been now examined in medulloblastoma and glioblastoma cells. Real-time PCR and ELISA revealed that under Hyp VEGF expression increased more than three fold in DAOY medulloblastoma cells; while, U87 glioblastoma cells - constitutively expressing high VEGF levels - showed no significant differences. Moreover, Hyp induced endothelial pro-angiogenic behaviour in a multi-parametric Matrigel colonisation assay, and down-modulation of pro-MMP-2 and pro-MMP-9 activities as measured by gelatin zymography. Should these results be confirmed in vivo for this and other types of CNS tumour, the antidepressant use of SJW extracts must be carefully re-considered, in particular for brain tumour patients.
Assuntos
Antidepressivos/farmacologia , Neoplasias Encefálicas/metabolismo , Neoplasias Cerebelares/metabolismo , Glioblastoma/metabolismo , Meduloblastoma/metabolismo , Floroglucinol/análogos & derivados , Terpenos/farmacologia , Fator A de Crescimento do Endotélio Vascular/metabolismo , Antidepressivos/efeitos adversos , Apoptose/efeitos dos fármacos , Neoplasias Encefálicas/irrigação sanguínea , Neoplasias Encefálicas/genética , Compostos Bicíclicos com Pontes/efeitos adversos , Compostos Bicíclicos com Pontes/farmacologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Neoplasias Cerebelares/irrigação sanguínea , Neoplasias Cerebelares/genética , Relação Dose-Resposta a Droga , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/metabolismo , Precursores Enzimáticos/metabolismo , Ensaio de Imunoadsorção Enzimática , Gelatinases/metabolismo , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Glioblastoma/irrigação sanguínea , Glioblastoma/genética , Humanos , Subunidade alfa do Fator 1 Induzível por Hipóxia/genética , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Meduloblastoma/irrigação sanguínea , Meduloblastoma/genética , Neovascularização Fisiológica/efeitos dos fármacos , Floroglucinol/efeitos adversos , Floroglucinol/farmacologia , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Terpenos/efeitos adversos , Transcrição Gênica/efeitos dos fármacos , Transfecção , Regulação para Cima , Fator A de Crescimento do Endotélio Vascular/genéticaRESUMO
(1) In a German study, very few patients informed their healthcare providers that they were taking St John's wort. (2) St John's wort is an enzyme inducer and can therefore accelerate the elimination of many drugs, including vitamin K antagonists, hormonal contraceptives and immunosuppressants. This leads to a potential loss of efficacy of these drugs when taken in combination with St John's wort. On the other hand, there may be a risk of overdose when St John's wort is withdrawn. (3) In practice, patients must be carefully questioned about all treatments they are taking, including herbal products they do not consider worth mentioning.
Assuntos
Anamnese , Fitoterapia/efeitos adversos , Compostos Bicíclicos com Pontes/efeitos adversos , Revelação , Interações Medicamentosas , Humanos , Hypericum/efeitos adversos , Floroglucinol/efeitos adversos , Floroglucinol/análogos & derivados , Terpenos/efeitos adversosRESUMO
Hypericins, hyperforin and flavonoids are discussed as the main components contributing to the antidepressant action of St. John's wort (Hypericum perforatum). Therefore, the objective of the two open phase I clinical trials was to obtain pharmacokinetic data of these constituents from a hypericum extract containing tablet: hypericin, pseudohypericin, hyperforin, the flavonoid aglycone quercetin, and its methylated form isorhamnetin. Each trial included 18 healthy male volunteers who received the test preparation, containing 900 mg dry extract of St John's wort (STW 3-VI, Laif 900), either as a single oral dose or as a multiple once daily dose over a period of 14 days. Concentration/time curves were determined for the five constituents, for 48 h after single dosing and for 24 h on day 14 at the end of 2 weeks of continuous daily dosing. After single dose intake, the key pharmacokinetic parameters were determined as follows: Hypericin: Area under the curve (AUC(0-infinity)) = 78.33 h x ng/ml, maximum plasma concentration (Cmax) = 3.8 ng/ml, time to reach Cmax (tmax) = 7.9 h, and elimination half-life (t1/2) = 18.71 h; pseudohypericin: AUC(0-infinity) = 97.28 h x ng/ml, Cmax = 10.2 ng/ml, tmax = 2.7 h, t1/2 = 17.19 h; hyperforin: AUC(0-infinity) = 1550.4 h x ng/ml, Cmax = 122.0 ng/ml, tmax = 4.5 h, t1/2 = 17.47 h. Quercetin and isorhamnetin showed two peaks of maximum plasma concentration separated by about 3-3.5 h. Quercetin: AUC(0-infinity) = 417.38 h x ng/ml, Cmax (1) = 89.5 ng/ml, tmax (1) = 1.0 h, Cma (2) = 79.1 ng/ml, tmax (2) = 4.4 h, t1/2 = 2.6 h; isorhamnetin: AUC(0-infinity) = 155.72 h x ng/ml, Cmax (1) = 12.5 ng/ml, tmax (1) = 1.4 h, Cmax (2) = 14.6 ng/ml, tmax (2) = 4.5 h, t1/2 = 5.61 h. Under steady state conditions reached during multiple dose administration similar results were obtained. Further pharmacokinetic characteristics calculated from the obtained data were the mean residence time (MRT), the lag-time, the peak-trough fluctuation (PTF), the lowest observed plasma concentration (Cmin), and the average plasma concentration (Cav). The data obtained for the five consitituents generally corresponded well with values previously published. The trial preparation was well tolerated.
Assuntos
Flavonóis/farmacocinética , Hypericum/química , Perileno/análogos & derivados , Floroglucinol/análogos & derivados , Quercetina/farmacocinética , Terpenos/farmacocinética , Adolescente , Adulto , Antracenos , Compostos Bicíclicos com Pontes/administração & dosagem , Compostos Bicíclicos com Pontes/efeitos adversos , Compostos Bicíclicos com Pontes/farmacocinética , Flavonóis/administração & dosagem , Flavonóis/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Perileno/administração & dosagem , Perileno/efeitos adversos , Perileno/farmacocinética , Floroglucinol/administração & dosagem , Floroglucinol/efeitos adversos , Floroglucinol/farmacocinética , Extratos Vegetais/efeitos adversos , Extratos Vegetais/análise , Extratos Vegetais/farmacocinética , Quercetina/administração & dosagem , Quercetina/efeitos adversos , Comprimidos , Terpenos/administração & dosagem , Terpenos/efeitos adversosRESUMO
OBJECTIVES: To determine the effects of Phloroglucinol in acceleration of labour and its adverse effects on mother and foetus. METHODS: A double blind randomized, placebo controlled trial was conducted on 100 patients in active phase of uncomplicated labour selected by convenient sampling. Patients were given Phloroglucinol or Placebo (distilled water) intravenously. Progress of labour was plotted on Partogram. Any adverse effects of the drug on mother and fetus were noted. Student's t-test was applied for statistical analysis. RESULTS: In patients receiving Phloroglucinol there was a mean 34% reduction in duration of 1st stage of labour and a mean 23% reduction in 2nd stage as compared to Placebo group respectively. Blood loss >500ml was observed in 2% patients. Otherwise there were no adverse effects on mother or foetus. CONCLUSION: Phloroglucinol shortens the duration of labour, is non toxic to both mother and fetus and does not cause primary post partum haemorrhage.